QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Naritoku, D. K Articles by Olson, W. H Search for Related Content PubMed PubMed Citation Articles by Naritoku, D. K Articles by Olson, W. H

NEUROLOGY

Effect of Cotherapy Reduction on Tolerability of Epilepsy Add-On Therapy: A Randomized Controlled Trial

Professor of Neurology and Pharmacology, School of Medicine, Southern Illinois University, Springfield, IL

Joseph F Hulihan, MD

Group Director, CNS Research, Clinical Affairs, Ortho-McNeil Pharmaceutical, Raritan, NJ

Lesley Kraut Schwarzman, MS

Assistant Director, CNS Projects, Ortho-McNeil Pharmaceutical

Marc Kamin, MD

Vice President, Clinical Trials, Ortho-McNeil Pharmaceutical

William H Olson, PhD

Senior Director, Quantitative Methodology, Ortho-McNeil Pharmaceutical

Reprints: Dr. Naritoku, Department of Neurology, Southern Illinois University, PO Box 19637, Springfield, IL 62794-9637, fax 217/545-8039, dnaritoku{at}siumed.edu

BACKGROUND: Adverse effects are the most common cause for failure of an antiepileptic drug (AED), especially when an AED is added to existing therapy. With the increased drug load, it may not be possible to titrate the newly added AED to effective doses. Reducing the dosage of AED cotherapy as the new drug is introduced may improve tolerability.

OBJECTIVE: To evaluate reduction of AED cotherapy as a strategy to improve tolerability and patient retention when a new AED is added to existing therapy.

METHODS: In a 20-week, randomized, open-label study, topiramate was initiated as add-on therapy in adults and adolescents (12 y of age) with inadequately controlled partial-onset seizures. Patients were randomized to receive treatment in which adverse events could be managed by adjustments in AED cotherapy (flex-dose group) or treatment in which AED cotherapy dosages remained fixed (fixed-dose group). Topiramate could be adjusted as needed in both groups. In the flex-dose group, patients exited randomized treatment when topiramate was discontinued. In the fixed-dose group, patients exited when AED cotherapy was reduced due to adverse events or when topiramate was discontinued. The primary study outcome was the percentage of patients exiting randomized treatment due to adverse events.

RESULTS: The flex-dose group comprised 297 patients; 302 patients were in the fixed-dose group. Significantly fewer patients in the flex-dose group exited the study due to adverse events (16% vs 23% in the fixed-dose group; p = 0.02). In the flex-dose group, 10% (17 of 168) of patients discontinued topiramate due to adverse events after AED cotherapy was reduced versus 22% (29 of 129) when AED cotherapy was not reduced.

CONCLUSIONS: Reduction of AED cotherapy is a useful strategy to improve tolerability and retention when topiramate is initiated as adjunctive therapy.

Key Words: antiepileptic drug, epilepsy, seizures, tolerability, topiramate

Published Online, February 8, 2005. www.theannals.com, DOI 10.1345/aph.1E403

This article has been cited by other articles:

				R. Korinthenberg and A. Schreiner Topiramate in Children With West Syndrome: A Retrospective Multicenter Evaluation of 100 Patients J Child Neurol, March 1, 2007; 22(3): 302 - 306. [Abstract] [PDF]